Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Related Citations for PubMed (Select 23427811)

1.

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials.

Nikolic D, Nikfar S, Salari P, Rizzo M, Ray KK, Pencina MJ, Mikhailidis DP, Toth PP, Nicholls SJ, Rysz J, Abdollahi M, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Curr Med Res Opin. 2013 May;29(5):435-51. doi: 10.1185/03007995.2013.779237. Epub 2013 Mar 11. Review.

PMID:
23427811
2.

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.

Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, Rizzo M, Rysz J, Abdollahi M, Nicholls SJ, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Pharmacol Res. 2013 Jun;72:35-44. doi: 10.1016/j.phrs.2013.03.007. Epub 2013 Mar 28.

PMID:
23542730
3.

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

Nikolic D, Banach M, Nikfar S, Salari P, Mikhailidis DP, Toth PP, Abdollahi M, Ray KK, Pencina MJ, Malyszko J, Rysz J, Rizzo M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Int J Cardiol. 2013 Oct 15;168(6):5437-47. doi: 10.1016/j.ijcard.2013.08.060. Epub 2013 Aug 28.

PMID:
24016544
5.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

6.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

7.

Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy.

Hoenig MR, Sellke FW.

Atherosclerosis. 2010 Jul;211(1):260-5. doi: 10.1016/j.atherosclerosis.2010.02.029. Epub 2010 Mar 1.

PMID:
20356594
8.

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.

Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL.

Curr Med Res Opin. 2007 Aug;23(8):2009-26.

PMID:
17659159
9.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

10.

Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.

Abujrad H, Mayne J, Ruzicka M, Cousins M, Raymond A, Cheesman J, Taljaard M, Sorisky A, Burns K, Ooi TC.

Atherosclerosis. 2014 Mar;233(1):123-9. doi: 10.1016/j.atherosclerosis.2013.12.030. Epub 2014 Jan 8.

PMID:
24529132
11.

Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.

Geng Q, Ren J, Chen H, Lee C, Liang W.

Curr Med Res Opin. 2013 Mar;29(3):181-8. doi: 10.1185/03007995.2013.766592. Epub 2013 Feb 6.

PMID:
23323878
12.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004289. doi: 10.1002/14651858.CD004289.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004289.

PMID:
19370598
13.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
14.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004289. doi: 10.1002/14651858.CD004289.pub4. Review.

PMID:
19588351
15.

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC.

BMJ. 2008 Mar 22;336(7645):645-51. doi: 10.1136/bmj.39472.580984.AE. Epub 2008 Feb 25. Review. Erratum in: BMJ. 2009;339:b2951.

16.

Is lipid management effective for all stages of CKD?.

Ku E, Campese V.

Blood Purif. 2013;35(1-3):26-30. doi: 10.1159/000345932. Epub 2013 Jan 22. Review.

PMID:
23343543
17.

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J.

Health Technol Assess. 2008 May;12(21):iii, xi-xiii, 1-212. Review.

18.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192
19.

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials.

McKinney JS, Kostis WJ.

Stroke. 2012 Aug;43(8):2149-56. doi: 10.1161/STROKEAHA.112.655894. Epub 2012 May 15. Review.

20.

Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials.

Li Y, Liu Y, Fu L, Mei C, Dai B.

PLoS One. 2012;7(4):e34450. doi: 10.1371/journal.pone.0034450. Epub 2012 Apr 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk